Skip to main content

Peer Review reports

From: A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China

Original Submission
2 May 2022 Submitted Original manuscript
8 May 2022 Author responded Author comments - Wentao Yang
10 May 2022 Author responded Author comments - Wentao Yang
Resubmission - Version 2
8 May 2022 Submitted Manuscript version 2
18 Nov 2022 Reviewed Reviewer Report
7 Dec 2022 Reviewed Reviewer Report
6 Jan 2023 Author responded Author comments - Wentao Yang
Resubmission - Version 3
6 Jan 2023 Submitted Manuscript version 3
7 Jan 2023 Author responded Author comments - Wentao Yang
Resubmission - Version 4
7 Jan 2023 Submitted Manuscript version 4
Publishing
9 Jan 2023 Editorially accepted
25 Jan 2023 Article published 10.1186/s12885-023-10531-z

You can find further information about peer review here.

Back to article page